ENA 2024 Poster PB437

An IND-Ready Anti-CD4 Monoclonal Antibody in Combination with PD-1 Inhibitors for the Treatment of Solid Tumors

Y. Nakano, L. Price, S.K. Dubey, I. Duthoit, P.A. Cayatte, H. Kim

Tregs, a subset of CD4+ T cells, suppress tumor immunity and reduce the effectiveness of cancer treatments. PD-1 inhibitor therapy often upregulates Tregs, diminishing efficacy. Combining PD-1 inhibitors with Treg depletion using anti-CD4 antibodies may counteract this negative feedback and enhance overall treatment effectiveness.

Our nonclinical data demonstrate that CC182, in combination with a PD-1 inhibitor, shows greater efficacy compared to PD-1 inhibitor treatment alone. Given its favorable safety profile, these findings support advancing to a first-in-human Phase 1 trial.

Download this Poster to Discover:

• An IND-ready anti-CD4 monoclonal antibody, CC182
• How the combination of CC182 with anti-PD1 outperformed treatment with anti-PD1 alone in vivo
• The safety and toxicology profile of CC182

Download the Poster Now!